Plain-English translation of NCT07465653 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new medication called HJB647 to see if it is safe and tolerable for people living with heart failure—a condition where the heart doesn't pump blood as strongly as it should. Researchers want to understand how your body processes this medication and whether it causes any unwanted side effects. You would receive either the new medication at two different doses or a placebo (a dummy pill with no active ingredient).
Heart failure with reduced ejection fraction is a serious condition that limits how well the heart works, and doctors are always looking for new treatment options that could help people feel better and live longer. This early-stage trial is designed to make sure this medication is safe before larger studies can test whether it actually improves outcomes for heart failure patients.
You likely qualify if…
You likely don't qualify if…
You would take capsules by mouth once daily for three consecutive days—either the new medication at a lower dose, the medication at a higher dose, or a placebo. You would stay at the research clinic during the three days of treatment so the medical team can closely watch for any side effects. You would return for a follow-up visit on Day 7 and receive a safety check-in call on Day 33.
AI-generated summary from trial data · Jul 16, 2026 · Not medical advice
United States
Canada